As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product. However, different salt forms or prodrugs of the same API do not meet the criteria for pharmaceutical equivalence.
Pharmaceutically equivalent drug products may also differ in inactive ingredients, impurity levels, shape, release mechanisms, packaging, and labeling. While strictly speaking, only identical drug products are truly bioequivalent and therapeutically equivalent, practical considerations lead to the general view that two drug products are bioequivalent when they do not significantly differ in the rate and extent of the API reaching the site of drug action.
Furthermore, differences in particle size, polymorphism, hydration state, impurities, stability, racemic mixtures, and biotechnology-derived drugs can impact pharmaceutical equivalence. Differences in physical attributes, excipients, sterile solutions, and overage also play a role in determining pharmaceutical equivalence.
In conclusion, achieving pharmaceutical equivalence involves meeting stringent standards across various drug composition and performance aspects, ensuring regulatory compliance and therapeutic effectiveness.
Pharmaceutical equivalents deliver the same amounts of active pharmaceutical ingredients or APIs over a similar dosing period.
Generic drugs are pharmaceutically equivalent to the reference drug when they contain the same amount of active pharmaceutical ingredient and have the same dosage form.
They must adhere to compendial standards for potency, content uniformity, disintegration time, and dissolution rate.
Drug content variations are permitted in modified-release dosage forms if the delivered drug amount remains identical to that of the innovator product.
However, different salt forms or prodrugs of the same API are not considered pharmaceutical equivalents under the FDA's definition.
Pharmaceutically equivalent products may contain different excipients or allowable impurities and may also vary in shape, packaging, labeling, and physical attributes.
API characteristics like particle size, polymorphism, purity, stability, and stereochemistry influence pharmaceutical equivalence.
Drug delivery systems, the dosage form’s physical attributes, sterility, overage, and manufacturing processes also affect its equivalence.
繁體中文
